ANN ARBOR, MI/ACCESSWIRE/July 6, 2022/Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health care company providing diagnostic and therapeutic products for companion animals, today announced that the acquisition of the assets of Revo Squared LLC ( “Revo”) was recently finalized.
Revo’s innovative MicroView digital cytology platform will provide veterinarians with best-in-class image quality while providing the first in-clinic automated slide preparation system. Slide preparation is an essential part of hematology and cytology. and slide preparation errors are the number one reason pathologists give for not being able to read a slide. The MicroView platform improves practice workflow efficiency by automating the process to ensure consistent smearing and staining to produce a readable slide.
Final development, manufacturing and distribution of the MicroView digital cytology platform will be moved to Zomedica’s new global manufacturing and distribution center in Roswell, Georgia to take advantage of site capital improvements, expanding manufacturing capacity and advanced technologies.
“We are excited to bring the MicroView platform to our new facility.” said Tony Blair, Chief Operating Officer of Zomedica. “We can easily capitalize on the success of our current high-quality manufacturing site and the experienced workforce already operating there – and we look forward to developing it further to bring MicroView to the veterinary market in 2023.”
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company that creates companion animal products with a focus on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that focus on patient health and practice health. Zomedica’s mission is to provide veterinarians with the ability to increase their productivity and revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Notice to readers
Except for statements of historical fact, this press release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is often characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other words similar, or statements that certain events or conditions “may” or “will” and include statements regarding our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Accordingly, there can be no assurance that the actual results achieved will be the same, in whole or in part, as those set forth in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management as of the date the statements are made, including assumptions regarding the ability to transfer Revo’s assets to Zomedica’s facilities, U.S. economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, our ability to successfully integrate and operate the Revo business, the adequacy of our budgeted capital and operating expenditures, cost, l the adequacy and availability of supplies needed for our operations, the fulfillment by our strategic partners of their obligations under our commercial agreements, our ability to carry out our business plans and our efforts to control costs and the impact of COVID-19 on our activities, our results and our financial situation.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause actual results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will produce the benefits discounted; uncertainty regarding the timing and results of development work and verification and validation studies; uncertainty about the timing and results of marketing efforts, as well as the cost of marketing efforts, including the cost of developing an internal sales force and managing our growth; uncertainty about our ability to successfully integrate and operate the Revo business; uncertainty about our ability to supply equipment and analytics in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies needed for our operations; uncertainty about the likelihood and timing of required regulatory approvals, as well as the availability and cost of capital; the ability to identify, develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditure necessary to maintain and improve the quality of products and services; technological developments and changes in laws and regulations; our ability to secure and maintain strategic relationships; the performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks related to permits and licenses, risks of intellectual property infringement, risks related to possible clinical trials and approvals regulatory requirements, risks related to the safety and efficacy of our products, the use of our products, the protection of intellectual property, risks related to the COVID-19 pandemic and its impact on our business operations in general , including our ability to develop and commercialize our products, and other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be considered exhaustive.
The forward-looking information contained in this press release is expressly qualified by this cautionary statement. We undertake no obligation to update forward-looking information to conform to actual results or to changes in our expectations, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.
Contact with Investor Relations:
PCG Advisory Group
Kirin Smith, President [email protected]
THE SOURCE: Zomedica Corp.
See the source version on accesswire.com: